

What to Buy, Sell and Hold



■ **Motilal Oswal** has a 'buy' rating on **Shree Cement** with a target price of ₹18,867. Shree Cement is likely to post an EBITDA CAGR of 29% over FY18-FY20 period, led by healthy volume growth and pricing improvement, said Motilal Oswal. Shree deserves to trade at premium valuations due to its superior return ratios and strong earnings growth. Shares of Shree Cement ended up 1.41% at ₹16,410 on Monday.

■ **Edelweiss Securities** has a 'buy' rating on **Fortis Healthcare** with a target price of ₹180. The brokerage believes that minority shareholders of Fortis Healthcare may not benefit from the deal involving demerger of its hospital business into Manipal Hospitals. Shares of Fortis Healthcare ended up 3% at ₹127.10 on Monday.

■ **Reliance Securities** has a 'buy' rating on **Kalpataru Power Transmission** with a target price of ₹550. The brokerage is bullish on the company due to its strong revenue and order visibility, sustained earnings momentum and likely improvement in return ratios in next two years. Shares of Kalpataru Power ended up 0.66% at ₹484.65 on Monday.

■ **Credit Suisse** has maintained 'outperform' rating on **Cipla** with a target price of ₹700. It expects earnings growth at Cipla to be the highest among large cap peers for the next three years as US margins normalise for the company. Credit Suisse said further price erosion risk for Cipla is the lowest in the sector due to low margin portfolio currently, with most of the products already heavily commoditised. Shares of Cipla ended up 6.10% at ₹576.40 on Monday.